Sanara MedTech Inc. Common Stock
SMTISanara MedTech Inc. is a medical technology company focused on developing, manufacturing, and marketing innovative products for wound care, regenerative medicine, and surgical applications. The company aims to improve patient outcomes through its portfolio of advanced medical solutions, emphasizing minimally invasive procedures and advanced healing technologies.
Company News
Sanara MedTech reported strong Q1 2026 results with 19% year-over-year revenue growth to $27.8 million, driven by increased sales of soft tissue repair products CellerateRX and BIASURGE. The company achieved GAAP net profitability with $0.4 million net income ($0.04 per diluted share), improved gross margins to 93%, and paid debt service entirely...
The Schall Law Firm is investigating Sanara MedTech Inc. for potential securities fraud related to the discontinuation of its Tissue Health Plus program announced on November 11, 2025. The company reported a $31.2 million net loss from discontinued operations, including a $26.5 million charge for the THP program, causing shares to fall 24.7%. Inv...
Holzer & Holzer, LLC is investigating potential federal securities law violations by Sanara MedTech after the company announced a strategic business realignment that resulted in a stock price drop.
Sanara MedTech reported Q2 2025 earnings with 28% revenue growth, driven by surgical segment performance. The company's value-based care segment (Tissue Health Plus) continues to face challenges, prompting a strategic review.
Biomimetic Innovations Ltd, an affiliate of PBC Biomed, has announced an exclusive license and distribution agreement with Sanara MedTech Inc. for the company's OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler. Sanara has also made a minority investment in Biomimetic Innovations Ltd.
